Caesars Entertainment misses Q2 earnings expectations, shares edge lower
LONDON - Ananda Pharma PLC (AQSE: ANA), a UK-based biopharmaceutical company specializing in cannabinoid medicines, announced that CEO Melissa Sturgess will present at the Talman House private investor conference in Zurich today. The company, which is engaged in developing treatments for chronic conditions such as epilepsy and endometriosis, is one of a select group invited to the exclusive Talman House event.
Sturgess is expected to discuss Ananda’s progress in cannabinoid drug development, emphasizing the potential of cannabinoids to address a range of chronic diseases. She noted the importance of pursuing a fully regulated drug development pathway to ensure patient access and shareholder returns. Ananda Pharma is currently advancing four clinical trials involving cannabinoid treatments.
Talman House, a private members’ organization, hosts gatherings for investors with an interest in the cannabis industry and related sectors. This Zurich event marks the second official meeting of Talman House members, who convene to explore market developments and investment opportunities.
Ananda Pharma’s leadership comprises successful entrepreneurs and a team of world-class scientists collaborating with highly regarded institutions such as the University of Edinburgh and University College London. The company’s trials in epilepsy are funded by NHS England and the National Institute for Health Research (NIHR), while NHS Scotland funds their endometriosis trials.
The Talman House event provides a platform for Ananda to showcase its vision and ongoing work to an audience of private investors. The company’s approach to drug development and its engagement with regulatory processes underscore its commitment to addressing the health and economic challenges posed by chronic diseases through the therapeutic application of cannabinoids.
This news is based on a press release statement from Ananda Pharma PLC.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.